Monoclonal Antibodies and the Preparative Use of Asymmetric Flow Field-Flow Fractionation (AF4)

Proteins—especially monoclonal antibodies (MABs)— have become increasingly important in pharmaceutical work. However, there are some important differences between conventional, chemically-synthesized drugs and proteins. Asymmetrical flow field-flow fractionation (AF4) is a well established method for sizing and quantifying different aggregate species in protein formulations. A major advantage of AF4 is the use of the formulation buffer of the protein as the mobile phase.